In accordance with Section 3 of the Articles of Association of Orion Corporation, 297,000 A shares have been converted into 297,000 B shares. The conversion has been entered into the Trade Register on 16 April 2019.
The total number of shares in Orion Corporation is 141,257,828 which, after the conversion, consists of 36,823,346 A shares and 104,434,482 B shares. The number of votes of the company's shares is after the conversion 840,901,402.
Orion Corporation
| Olli Huotari SVP, Corporate Functions | Jari Karlson CFO |
Contact person:
Terhi Ormio, Vice President, Communications, tel. +358 10 426 4646
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi/en
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2018 amounted to EUR 977 million and the company had about 3,200 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.